United Therapeutics Co. (NASDAQ:UTHR) COO Sells $3,707,100.00 in Stock

United Therapeutics Co. (NASDAQ:UTHR) COO Michael Benkowitz sold 10,000 shares of the business’s stock in a transaction on Monday, January 27th. The stock was sold at an average price of $370.71, for a total transaction of $3,707,100.00. Following the sale, the chief operating officer now directly owns 2,577 shares in the company, valued at approximately $955,319.67. The trade was a 79.51 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Michael Benkowitz also recently made the following trade(s):

• On Tuesday, January 21st, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $364.91, for a total transaction of $3,649,100.00.
• On Monday, January 13th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $364.62, for a total value of $3,646,200.00.
• On Monday, December 30th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $356.68, for a total value of $3,566,800.00.
• On Monday, December 23rd, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $361.95, for a total transaction of $3,619,500.00.
• On Monday, November 25th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $372.75, for a total transaction of $3,727,500.00.
• On Monday, November 11th, Michael Benkowitz sold 15,000 shares of United Therapeutics stock. The shares were sold at an average price of $407.32, for a total transaction of $6,109,800.00.
• On Thursday, November 7th, Michael Benkowitz sold 15,000 shares of United Therapeutics stock. The stock was sold at an average price of $401.44, for a total value of $6,021,600.00.
• On Friday, November 1st, Michael Benkowitz sold 14,700 shares of United Therapeutics stock. The shares were sold at an average price of $374.46, for a total transaction of $5,504,562.00.

United Therapeutics Price Performance

Shares of UTHR traded up $1.29 during midday trading on Tuesday, hitting $370.85. 320,223 shares of the company traded hands, compared to its average volume of 285,807. The stock has a 50-day moving average of $365.40 and a 200-day moving average of $356.35. United Therapeutics Co. has a one year low of $208.62 and a one year high of $417.82. The firm has a market cap of $16.56 billion, a P/E ratio of 16.29, a PEG ratio of 0.95 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.16 by $0.23. The company had revenue of $748.90 million during the quarter, compared to analyst estimates of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm’s quarterly revenue was up 22.9% on a year-over-year basis. During the same quarter last year, the company earned $5.38 earnings per share. Sell-side analysts forecast that United Therapeutics Co. will post 25.22 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on UTHR shares. StockNews.com raised shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 16th. TD Cowen raised their price target on shares of United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a research report on Monday, October 21st. Argus upped their price objective on shares of United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. UBS Group lifted their target price on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. Finally, HC Wainwright lifted their price target on United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $378.36.

Hedge Funds Weigh In On United Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. Newbridge Financial Services Group Inc. bought a new stake in shares of United Therapeutics in the 4th quarter valued at about $25,000. USA Financial Formulas purchased a new stake in shares of United Therapeutics during the third quarter valued at approximately $33,000. Brooklyn Investment Group purchased a new position in shares of United Therapeutics in the third quarter worth $33,000. Capital Performance Advisors LLP bought a new stake in United Therapeutics during the 3rd quarter valued at $82,000. Finally, MassMutual Private Wealth & Trust FSB boosted its position in United Therapeutics by 31.9% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock valued at $85,000 after buying an additional 58 shares during the period. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.